ABBV AbbVie Inc. Insider Trading

SVP David Ryan sold 5,230 shares of ABBV at $233.56; retained 2,654 shares (-66.3% of holdings).

Purdue David Ryan, as SVP and Controller at AbbVie, executed a substantial sale of 5,230 shares on 2026-03-04 at $233.56 per share, reducing his holdings from 7,884 to 2,654 shares—a reduction of 66.3% of his prior position. The stock is currently trading at $230.11, only 5.8% below its 52-week high of $244.38, and has gained 6.0% over the prior 30 days. The company reported latest-quarter revenue of $15,776,000,000.00 with net income of $186,000,000.00 and achieved 8.6% annual revenue growth. This sale represents a material reduction in his direct equity stake, though the controller retains meaningful holdings, suggesting neither full conviction departure nor complete disengagement from the company's future performance.

EVP/GC Perry sold 18.7K shares ($4.4M) across 3 transactions at blended $234.39, reducing holdings by 80.2%

Siatis Perry C, serving as EVP, General Counsel and Secretary, executed three separate sales on 2026-03-02 totaling 18,668 shares for $4,375,549.33, reducing his holdings from 23,287 shares to 4,619 shares—an 80.2% reduction in position size. The execution prices ranged from $233.51 to $235.26, clustering tightly around the $234.39 blended average, slightly below the current price of $233.86. At ABBV specifically, Perry's prior four measurable sales (Feb–Mar 2025) all achieved negative 90-day returns ranging from -9.6% to -11.4%, establishing a 100% well-timed rate at this ticker; this new sale arrives near the 52-week high of $244.38 (only -4.3% back), presenting a structurally similar high-conviction-exit signal as his prior sales. The magnitude—an 80% portfolio reduction by a seated executive—combined with his demonstrated precision timing at this ticker warrants investor attention to potential forward-looking signals embedded in his exit.

EVP/GC Siatis Perry sells 22,381 shares of ABBV at $230.00 for $5.1M, reducing holdings 37% to 38.1K shares

Siatis Perry, EVP and General Counsel, executed a substantial open-market sale of 22,381 shares at $230.00, totaling $5,147,630.00 and reducing his holdings by 37% from 60,518 to 38,137 shares. His prior five trades at ABBV all showed negative 90-day returns averaging -10.0%, with a 100% well-timed rate at this ticker—a pattern consistent with his broader cross-ticker track record showing a 100% 90-day well-timed rate across 9 prior sells. At the current price of $232.08, the stock sits -5.0% from its 52-week high of $244.38, suggesting this sale occurred near elevated valuation within the recent trading range. The substantial reduction in a senior executive's concentrated position, combined with his demonstrated historical precision in sell timing, represents a material signal warranting attention to near-term valuation dynamics at AbbVie.

EVP COO SALEKI-GERHARDT sold 42,370 shares of ABBV at $198.42 on 2025-08-12; post-sale holdings 177,292 shares.

SALEKI-GERHARDT AZITA, EVP and Chief Operations Officer, sold 42,370 shares (19.3% of pre-transaction holdings) for $8,407,055.40. The sale price of $198.42 represents 3.0% below the current price of $204.68 and sits within the 52-week range of $164.99–$216.66. Her single prior sale at ABBV on 2024-02-21 was well-timed, with a negative 90-day return of -6.2%, indicating the stock declined after that sale. The current transaction occurs in a period of strong recent momentum: the stock is up 9.8% over 30 days and 11.2% over 90 days. Her cross-ticker track record shows a 100% well-timed rate on 1 prior sell, though with an average 90-day return of -6.2%, reflecting the timing of prior sales relative to subsequent declines. The significance is moderate: a substantial absolute dollar sale by a senior operational executive, but occurring on a stock with elevated recent gains and valuations (P/E of 96.09), leaving the timing context ambiguous without additional disclosure context.

EVP Nicholas Donoghoe sold 13,295 shares at blended $198.51; reduces stake by 18.6% to 58,247 shares

On 2025-08-05, Nicholas Donoghoe, EVP and Chief Business/Strategy Officer, executed 2 separate sales totaling 13,295 shares for $2,639,252.88 at a blended average price of $198.51. This represents an 18.6% reduction of his holdings from 71,542 to 58,247 shares. The current stock price of $198.86 is within striking distance of the transaction prices ($198.27 and $198.59), suggesting the sales occurred near recent price levels. Donoghoe's cross-ticker track record shows 1 prior sell with a 90-day well-timed rate of 100.00%, and at ABBV specifically, his March 2024 sale showed -2.8% 90-day return—both instances where the stock fell after his sales. While the multi-transaction structure and magnitude of this sale warrant monitoring, the stock's +4.8% 30-day performance since the August 5 transaction date and the company's solid revenue base ($15,423,000,000 quarterly) provide context that this is a material but not extraordinary move by a senior strategic officer.

EVP Stewart Jeffrey Ryan sells 58,832 shares for $12,359,504.28 at ABBV; divests 52.5% of holdings post-transaction.

Stewart Jeffrey Ryan, Chief Commercial Officer of AbbVie, executed two separate sales on 2025-03-31 totaling 58,832 shares at a blended average price of $210.08, reducing his holdings from 112,066 shares to 53,234 shares (a 52.5% reduction). At the time of sale, the stock was trading near its 52-week highs ($216.66), having declined only 5.3% from the peak. Notably, across his cross-ticker track record, Ryan's prior 3 sales achieved a 100.00% well-timed rate at the 90-day mark, with prior sales at ABBV specifically all showing negative 90-day returns (ranging from -5.6% to -5.8%). The current price of $205.19 is already 5.3% below the 52-week high, and the 30-day change of -3.0% suggests early movement consistent with his historical post-sale patterns. This substantial reduction in position size, combined with the insider's established track record of well-timed sells and the stock's proximity to its annual high, warrants investor attention to near-term price momentum.

CFO Scott T Reents sold 17,644 shares of ABBV at $212.34 for $3.7M, reducing holdings by -60.4%.

Scott T Reents, EVP and Chief Financial Officer, executed an open-market sale of 17,644 shares at $212.34 on 2025-03-14, reducing his ABBV holdings from 29,221 to 11,577 shares. The sale occurred at a price within 1.3% of the 52-week high, and notably, the stock has appreciated 10.9% over the trailing 30 days and 23.6% over the trailing 90 days since the transaction. His cross-ticker track record shows a 100.00% well-timed rate on prior sells, and his singular prior ABBV sale in February 2024 was similarly well-timed with a -10.8% 90-day return following that trade. The substantial reduction in absolute position size warrants investor attention to whether operational or portfolio factors are driving the sale, though the timing relative to recent upward momentum and the CFO's demonstrated track record of selling before declines merit monitoring.

EVP Chief HR Officer Richmond sells 21,250 shares in 3 transactions for $4.5M at $210.45 avg; holdings drop to 6,130 shares

Timothy J. Richmond, EVP and Chief HR Officer, executed 3 separate sales totaling 21,250 shares for $4,472,038.78 at a blended average price of $210.45 on 2025-03-03. This represents a substantial reduction of his ABBV holdings from 27,380 shares to 6,130 shares, a -77.6% decrease in position size. The stock is trading at $207.76 currently, down -1.8% from its 52-week high of $211.48, and has appreciated +13.0% over the past 30 days and +17.7% over the past 90 days. Richmond's cross-ticker track record shows 10 prior sells with a 100.00% well-timed rate at the 90-day mark, though at ABBV specifically, his 5 prior transactions on 2025-02-26 remain outcome-not-yet-measurable; this large sale follows closely on those recent sales just one week prior.

Director Richard A Gonzalez sold 98,628 shares for $20.3M at blended avg $205.45; post-sale holdings 388.9K shares.

Richard A Gonzalez, a Director of AbbVie, executed 2 separate sales totaling 98,628 shares for $20,263,019.64, reducing his holdings by 20.2% from 487,557 to 388,929 shares. The sales occurred at $205.11 on 2025-02-28 and $210.53 on 2025-03-03, bracketing a modest price move; at the current price of $207.76, the blended average transaction price of $205.45 remains competitively positioned just below the 52-week high of $211.48. His prior 5 sales at ABBV show mixed timing outcomes: 3 of 5 were well-timed at the 90-day mark, though recent sales on 2024-08-05 and 2024-07-17 saw the stock rise 5.6% and 10.8% respectively over 30 days afterward, indicating the insider sold into strength rather than weakness on those occasions. With AbbVie trading at a P/E of 80.84 and the stock up 13.0% over the past 30 days and 17.7% over 90 days, this sale represents a material reduction of a senior insider's position at elevated valuations and following a pronounced uptrend.

EVP/GC Siatis Perry sold 27,900 shares at blended avg $208.69, reducing holdings 85.8%, totaling $5.8M.

Siatis Perry C, EVP, General Counsel and Secretary at AbbVie, executed 4 separate sales totaling 27,900 shares for $5,822,401.63 over February 28 and March 3, 2025, reducing his holdings from 32,519 shares to 4,619 shares—a reduction of 85.8%. This substantial reduction occurred as the stock traded within 1.8% of its 52-week high ($211.48) and has appreciated 13.0% over the prior 30 days and 17.7% over the prior 90 days. Notably, Perry's prior 5 trades at ABBV all showed negative 90-day returns, with 3 of 3 measurable outcomes well-timed at the 90-day mark, suggesting a consistent pattern of selling ahead of subsequent declines at this ticker. The current near-peak pricing and strong recent momentum are contextual factors investors should monitor alongside the near-complete liquidation of his personal stake.